Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitoxantrone Liposome in NMOSD
NCT05551598Phase 2Completed
- Sponsor
- CSPC Zhongnuo Pharmaceutical
- Start
- Nov 2022
- Primary completion
- Jul 2024
- Modality
- Lipid-based Nanoparticles, CAR-T Cells, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells in Neuromyelitis Optica Spectrum Disorder (NMOSD) (3 arms), sponsored by CSPC Zhongnuo Pharmaceutical. Primary endpoint: Time to First Protocol-defined Relapse. Started Nov 2022; status: completed.
02
Drugs
mitoxantrone hydrochloride liposome injection + fludarabine + CD19 CAR-T cells
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT05551598.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05551598.